197 related articles for article (PubMed ID: 33232357)
1. Assessment of mucin-related gene alterations following treatment with rebamipide ophthalmic suspension in Sjögren's syndrome-associated dry eyes.
Shoji J; Inada N; Tomioka A; Yamagami S
PLoS One; 2020; 15(11):e0242617. PubMed ID: 33232357
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory effects of rebamipide eyedrop administration on ocular lesions in a murine model of primary Sjögren's syndrome.
Arakaki R; Eguchi H; Yamada A; Kudo Y; Iwasa A; Enkhmaa T; Hotta F; Mitamura-Aizawa S; Mitamura Y; Hayashi Y; Ishimaru N
PLoS One; 2014; 9(5):e98390. PubMed ID: 24866156
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Short-Term Effects of Diquafosol and Rebamipide on Mucin 5AC Level on the Rabbit Ocular Surface.
Hori Y; Kageyama T; Sakamoto A; Shiba T; Nakamura M; Maeno T
J Ocul Pharmacol Ther; 2017; 33(6):493-497. PubMed ID: 28346860
[TBL] [Abstract][Full Text] [Related]
4. Alterations of the ocular surface epithelial MUC16 and goblet cell MUC5AC in patients with atopic keratoconjunctivitis.
Dogru M; Matsumoto Y; Okada N; Igarashi A; Fukagawa K; Shimazaki J; Tsubota K; Fujishima H
Allergy; 2008 Oct; 63(10):1324-34. PubMed ID: 18782111
[TBL] [Abstract][Full Text] [Related]
5. Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in Sjögren syndrome patients with or without punctal occlusions.
Arimoto A; Kitagawa K; Mita N; Takahashi Y; Shibuya E; Sasaki H
Cornea; 2014 Aug; 33(8):806-11. PubMed ID: 24977983
[TBL] [Abstract][Full Text] [Related]
6. Two Patients with Dry Eye Disease Followed Up Using an Expression Assay of Ocular Surface Mucin.
Machida Y; Shoji J; Harada N; Inada N
Case Rep Ophthalmol; 2016; 7(1):208-15. PubMed ID: 27194990
[TBL] [Abstract][Full Text] [Related]
7. Graft Versus Host Disease-Associated Dry Eye: Role of Ocular Surface Mucins and the Effect of Rebamipide, a Mucin Secretagogue.
Shamloo K; Barbarino A; Alfuraih S; Sharma A
Invest Ophthalmol Vis Sci; 2019 Nov; 60(14):4511-4519. PubMed ID: 31675422
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Ocular Surface Mucin Expression After Topical Ophthalmic Drug Administration in Dry Eye-Induced Mouse Model.
Moon I; Kang HG; Yeo A; Noh H; Kim HC; Song JS; Ji YW; Lee HK
J Ocul Pharmacol Ther; 2018 Nov; 34(9):612-620. PubMed ID: 30325678
[TBL] [Abstract][Full Text] [Related]
9. Enhanced expression of SAM-pointed domain-containing Ets-like factor in chronic rhinosinusitis with nasal polyps.
Bai J; Miao B; Wu X; Luo X; Ma R; Zhang J; Li L; Shi J; Li H
Laryngoscope; 2015 Mar; 125(3):E97-103. PubMed ID: 25376946
[TBL] [Abstract][Full Text] [Related]
10. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjögren syndrome.
Argüeso P; Balaram M; Spurr-Michaud S; Keutmann HT; Dana MR; Gipson IK
Invest Ophthalmol Vis Sci; 2002 Apr; 43(4):1004-11. PubMed ID: 11923240
[TBL] [Abstract][Full Text] [Related]
11. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
[TBL] [Abstract][Full Text] [Related]
12. The effects of 2% rebamipide ophthalmic solution on the tear functions and ocular surface of the superoxide dismutase-1 (sod1) knockout mice.
Ohguchi T; Kojima T; Ibrahim OM; Nagata T; Shimizu T; Shirasawa T; Kawakita T; Satake Y; Tsubota K; Shimazaki J; Ishida S
Invest Ophthalmol Vis Sci; 2013 Nov; 54(12):7793-802. PubMed ID: 24168989
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye.
Ueda K; Matsumiya W; Otsuka K; Maeda Y; Nagai T; Nakamura M
BMC Ophthalmol; 2015 Jun; 15():58. PubMed ID: 26048396
[TBL] [Abstract][Full Text] [Related]
14. The increase of aqueous tear volume by diquafosol sodium in dry-eye patients with Sjögren's syndrome: a pilot study.
Yokoi N; Kato H; Kinoshita S
Eye (Lond); 2016 Jun; 30(6):857-64. PubMed ID: 27055679
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of rebamipide on transmembrane mucin biosynthesis in stratified ocular surface epithelial cells.
Uchino Y; Woodward AM; Argüeso P
Exp Eye Res; 2016 Dec; 153():1-7. PubMed ID: 27725198
[TBL] [Abstract][Full Text] [Related]
16. Secreted Mucins on the Ocular Surface.
Hori Y
Invest Ophthalmol Vis Sci; 2018 Nov; 59(14):DES151-DES156. PubMed ID: 30481820
[TBL] [Abstract][Full Text] [Related]
17. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye.
Kinoshita S; Oshiden K; Awamura S; Suzuki H; Nakamichi N; Yokoi N;
Ophthalmology; 2013 Jun; 120(6):1158-65. PubMed ID: 23490326
[TBL] [Abstract][Full Text] [Related]
18. Spdef null mice lack conjunctival goblet cells and provide a model of dry eye.
Marko CK; Menon BB; Chen G; Whitsett JA; Clevers H; Gipson IK
Am J Pathol; 2013 Jul; 183(1):35-48. PubMed ID: 23665202
[TBL] [Abstract][Full Text] [Related]
19. Concentrations of MUC16 and MUC5AC using three tear collection methods.
Ablamowicz AF; Nichols JJ
Mol Vis; 2017; 23():529-537. PubMed ID: 28761326
[TBL] [Abstract][Full Text] [Related]
20. Randomized Comparison Between Rebamipide Ophthalmic Suspension and Diquafosol Ophthalmic Solution for Dry Eye After Penetrating Keratoplasty.
Kobashi H; Kamiya K; Shimizu K
J Ocul Pharmacol Ther; 2017; 33(1):13-18. PubMed ID: 27937084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
